Language:

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

Journal of clinical immunology, 2022-10, Vol.42 (7), p.1360-1370 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 ;2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. ;The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. ;ISSN: 0271-9142 ;EISSN: 1573-2592 ;DOI: 10.1007/s10875-022-01308-3 ;PMID: 35764767

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
Author: Eto, Shohei ; Nukui, Yoko ; Tsumura, Miyuki ; Nakagama, Yu ; Kashimada, Kenichi ; Mizoguchi, Yoko ; Utsumi, Takanori ; Taniguchi, Maki ; Sakura, Fumiaki ; Noma, Kosuke ; Yoshida, Yusuke ; Ohshimo, Shinichiro ; Nagashima, Shintaro ; Okamoto, Keisuke ; Endo, Akifumi ; Imai, Kohsuke ; Kanegane, Hirokazu ; Ohnishi, Hidenori ; Hirata, Shintaro ; Sugiyama, Eiji ; Shime, Nobuaki ; Ito, Masanori ; Ohge, Hiroki ; Kido, Yasutoshi ; Bastard, Paul ; Casanova, Jean-Laurent ; Ohara, Osamu ; Tanaka, Junko ; Morio, Tomohiro ; Okada, Satoshi
Subjects: Autoantibodies ; Biomedical and Life Sciences ; Biomedicine ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; Enzyme-linked immunosorbent assay ; Escherichia coli ; Humans ; Immunology ; Infections ; Infectious Diseases ; Interferon ; Interferon Type I ; Internal Medicine ; Japan - epidemiology ; Male ; Medical Microbiology ; Original ; Original Article ; Pneumonia
Is Part Of: Journal of clinical immunology, 2022-10, Vol.42 (7), p.1360-1370
Description: Purpose Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1% of individuals under the age of 60 in the general population, with the prevalence increasing among those over 65. Neutralizing autoantibodies (naAbs) to type I IFNs have been found in at least 15% of patients with life-threatening COVID-19 pneumonia in several cohorts of primarily European descent. We aimed to evaluate the prevalence of aAbs and naAbs to IFN-α2 or IFN-ω in Japanese patients who suffered from COVID-19 as well as in the general population. Methods Patients who suffered from COVID-19 ( n = 622, aged 0–104) and an uninfected healthy control population ( n = 3,456, aged 20–91) were enrolled in this study. The severities of the COVID-19 patients were as follows: critical ( n = 170), severe ( n = 235), moderate ( n = 112), and mild ( n = 105). ELISA and ISRE reporter assays were used to detect aAbs and naAbs to IFN-α2 and IFN-ω using E. coli -produced IFNs. Results In an uninfected general Japanese population aged 20–91, aAbs to IFNs were detected in 0.087% of individuals. By contrast, naAbs to type I IFNs (IFN-α2 and/or IFN-ω, 100 pg/mL) were detected in 10.6% of patients with critical infections, 2.6% of patients with severe infections, and 1% of patients with mild infections. The presence of naAbs to IFNs was significantly associated with critical disease ( P = 0.0012), age over 50 ( P = 0.0002), and male sex ( P = 0.137). A significant but not strong correlation between aAbs and naAbs to IFN-α2 existed ( r = − 0.307, p value < 0.0001) reinforced the importance of measuring naAbs in COVID-19 patients, including those of Japanese ancestry. Conclusion In this study, we revealed that patients with pre-existing naAbs have a much higher risk of life-threatening COVID-19 pneumonia in Japanese population.
Publisher: New York: Springer US
Language: English
Identifier: ISSN: 0271-9142
EISSN: 1573-2592
DOI: 10.1007/s10875-022-01308-3
PMID: 35764767
Source: AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

Searching Remote Databases, Please Wait